Reaktionsgleichung
[CH:1]1([C:4]2[C:5]([O:13][C@@H:14]([CH3:19])[C:15]([F:18])([F:17])[F:16])=[CH:6][C:7]([C:10]([OH:12])=O)=[N:8][CH:9]=2)[CH2:3][CH2:2]1.[NH2:20][C:21]([CH3:29])([CH2:24][S:25]([CH3:28])(=[O:27])=[O:26])[C:22]#[N:23]>>[C:22]([C:21]([NH:20][C:10]([C:7]1[CH:6]=[C:5]([O:13][C@@H:14]([CH3:19])[C:15]([F:18])([F:17])[F:16])[C:4]([CH:1]2[CH2:2][CH2:3]2)=[CH:9][N:8]=1)=[O:12])([CH3:29])[CH2:24][S:25]([CH3:28])(=[O:27])=[O:26])#[N:23]Komponenten
3
Edukt 2
Produkt 1
Versuchsvorschrift
The title compound was synthesized in analogy to Example 78e, using 5-Cyclopropyl-4-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-pyridine-2-carboxylic acid (Example 68a) and 2-Amino-3-methanesulfonyl-2-methyl-propionitrile (Example 80a) as starting materials and isolated (503 mg, 54%) as a white solid; MS (ESI, m/z): 420.4 (M+H+).
Aufarbeitung
- customisolated (503 mg, 54%) as a white solid
Quellen und Nachweise
- ORD-Eintrag
- ord-beabf6759eaa4f24aa37fdbac47c755a
- Quelldatensatz
- uspto-grants-2016_08
- Patentnummer
- US09409866B2
Verknüpfte Notizen
Wird geladen…